Technical Analysis for AYTUW - Aytu Bioscience Inc. Wt

Grade Last Price % Change Price Change
grade F 0.089 -1.11% -0.0010
AYTUW closed down 1.11 percent on Friday, January 24, 2020, on 3 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical AYTUW trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 20 DMA Bullish -1.11%
Stochastic Buy Signal Bullish -1.11%
Narrow Range Bar Range Contraction -1.11%
Wide Bands Range Expansion -1.11%
Gapped Up Strength -1.11%
Oversold Stochastic Weakness -1.11%
Older signals for AYTUW ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Aytu is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. We are currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, urinary tract infections and male infertility. We currently market Natesto (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel. Natesto is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. We also currently market ProstaScint (capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. We also market Primsol (trimethoprim hydrochloride) — the only FDA-approved trimethoprim-only oral solution for urinary tract infections. We have a focused pipeline, including MiOXSYSTM, a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic Area and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S.
Medicine RTT Pharmaceutical Organ Systems Alcohols Prostate Cancer Hormones Ketones Testosterone Urinary Tract Infection Androstanes Hypogonadism Testosterone Replacement Therapy Urinary Tract Infections U.S. Food And Drug Administration In Vitro Diagnostic Device Androgen Replacement Therapy Indium (111in) Capromab Pendetide Male Infertility Trimethoprim Only Oral Solution Urological Cancers

Is AYTUW a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 1.2
52 Week Low 0.02
Average Volume 6,887
200-Day Moving Average 0.0000
50-Day Moving Average 0.0917
20-Day Moving Average 0.0784
10-Day Moving Average 0.0620
Average True Range 0.0309
ADX 12.01
+DI 51.2595
-DI 42.7317
Chandelier Exit (Long, 3 ATRs ) 0.0813
Chandelier Exit (Short, 3 ATRs ) 0.1267
Upper Bollinger Band 0.1762
Lower Bollinger Band -0.0194
Percent B (%b) 0.55
BandWidth 249.4898
MACD Line -0.0096
MACD Signal Line -0.0081
MACD Histogram -0.0016
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0890
Resistance 3 (R3) 0.0890 0.0890 0.0890
Resistance 2 (R2) 0.0890 0.0890 0.0890 0.0890
Resistance 1 (R1) 0.0890 0.0890 0.0890 0.0890 0.0890
Pivot Point 0.0890 0.0890 0.0890 0.0890 0.0890
Support 1 (S1) 0.0890 0.0890 0.0890 0.0890 0.0890
Support 2 (S2) 0.0890 0.0890 0.0890 0.0890
Support 3 (S3) 0.0890 0.0890 0.0890
Support 4 (S4) 0.0890